or Try an Advanced Search...

    Technical Analysis for GHRS - GH Research PLC

    Grade Last Price % Change Price Change
    B 10.95 13.94% 1.34
    GHRS closed up 13.94 percent on Wednesday, November 20, 2024, on 1.49 times normal volume. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Up Up
    Historical GHRS trend table...
    Date Alert Name Type % Chg
    Crossed Above 200 DMA Bullish 0.00%
    Expansion Breakout Bullish Swing Setup 0.00%
    Stochastic Reached Overbought Strength 0.00%
    Upper Bollinger Band Walk Strength 0.00%
    Multiple of Ten Bullish Other 0.00%
    Wide Bands Range Expansion 0.00%
    Above Upper BB Strength 0.00%
    Overbought Stochastic Strength 0.00%
    Up 3 Days in a Row Strength 0.00%
    Up 4 Days in a Row Strength 0.00%
    Older End-of-Day Signals for GHRS ...

       Recent Intraday Alerts

    Alert Time
    Rose Above Previous Day's High about 22 hours ago
    Up 1% about 22 hours ago
    Upper Bollinger Band Resistance about 22 hours ago
    60 Minute Opening Range Breakdown 1 day ago
    Possible NR7 1 day ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    GHRS Chart by TradingView
    Basic chart:

    Profile

    GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that is being investigated in the Phase 2 part of an ongoing Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate that is in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was founded in 2018 and is based in Dublin, Ireland.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Psychoactive Drugs Entheogens Treatment Resistant Depression Psychiatric And Neurological Disorders N Dimethyltryptamine

    Is GHRS a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 14 GH Research GAAP EPS of -$0.23 beats by $0.02
    Nov 14 GH Research Reports Third Quarter 2024 Financial Results and Provides Business Updates
    Nov 10 We Think GH Research (NASDAQ:GHRS) Can Afford To Drive Business Growth
    Sep 9 GH Research (GHRS) Moves to Buy: Rationale Behind the Upgrade
    Sep 9 After Plunging -18.19% in 4 Weeks, Here's Why the Trend Might Reverse for GH Research (GHRS)
    Sep 3 GH Research Reports Second Quarter 2024 Financial Results and Provides Business Updates
    Sep 3 GH Research Announces Appointment of Dr. Velichka “Villy” Valcheva to Chief Executive Officer
    Jun 2 GH Research (NASDAQ:GHRS) Is In A Good Position To Deliver On Growth Plans
    May 31 Psychedelic stocks mixed as FDA comments on MDMA therapy (update)
    See more GHRS news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 14.99
    52 Week Low 5.05
    Average Volume 63,557
    200-Day Moving Average 10.15
    50-Day Moving Average 7.87
    20-Day Moving Average 8.67
    10-Day Moving Average 9.28
    Average True Range 0.80
    RSI (14) 78.72
    ADX 28.03
    +DI 32.91
    -DI 10.14
    Chandelier Exit (Long, 3 ATRs) 8.69
    Chandelier Exit (Short, 3 ATRs) 9.42
    Upper Bollinger Bands 10.24
    Lower Bollinger Band 7.11
    Percent B (%b) 1.23
    BandWidth 36.10
    MACD Line 0.55
    MACD Signal Line 0.36
    MACD Histogram 0.1911
    Fundamentals Value
    Market Cap 569.63 Million
    Num Shares 52 Million
    EPS -0.79
    Price-to-Earnings (P/E) Ratio -13.86
    Price-to-Sales 0.00
    Price-to-Book 1.84
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 13.34
    Resistance 3 (R3) 13.12 12.10 12.94
    Resistance 2 (R2) 12.10 11.50 12.21 12.80
    Resistance 1 (R1) 11.53 11.12 11.82 11.75 12.67
    Pivot Point 10.51 10.51 10.66 10.62 10.51
    Support 1 (S1) 9.94 9.91 10.23 10.16 9.23
    Support 2 (S2) 8.92 9.53 9.03 9.10
    Support 3 (S3) 8.35 8.92 8.96
    Support 4 (S4) 8.57